Skip to main content
Premium Trial:

Request an Annual Quote

Athersys Withdraws Proposed $115M IPO

NEW YORK, April 17 – Athersys, which markets its Random Activation of Gene Expression technology for correlation of protein function and gene structure, withdrew its proposed $115 initial public offering in a filing with the Securities and Exchange Commission Tuesday. 

Athersys said it was canceling the IPO due to market conditions. But the Cleveland-based company said it might still sell shares in a private offering.

RAGE technology works by randomly activating genes, than tagging them in different samples. By detecting these tagged genes in diseased cells, researchers can correlate gene expression with disease processes. 

This cancellation is the latest in a series of public offering withdrawals by genomics companies in recent months. DoubleTwist withdrew a proposed IPO in March, Genometrix cancelled its IPO in February, and in October, Orchid withdrew plans for a follow-on offering.  
The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.